Compare MPA & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPA | STIM |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.1M | 140.6M |
| IPO Year | 1994 | 2018 |
| Metric | MPA | STIM |
|---|---|---|
| Price | $11.39 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 32.2K | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $52,776,000.00 |
| Revenue This Year | N/A | $11.10 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.50 | $0.80 |
| 52 Week High | $11.65 | $4.84 |
| Indicator | MPA | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 61.08 | 49.24 |
| Support Level | $11.16 | $1.23 |
| Resistance Level | $11.49 | $1.80 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 94.64 | 22.49 |
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with an investment objective to provide shareholders with as high a level of current income exempt from U.S. federal and Pennsylvania income taxes as is consistent with its investment policies and prudent investment management. The Fund seeks to achieve its investment objective by investing, as a fundamental policy, at least 80% of an aggregate of the Fund's net assets and the proceeds of any borrowings for investment purposes, in a portfolio of municipal obligations issued by or on behalf of the State of Pennsylvania, its political subdivisions, agencies, and instrumentalities and by other qualifying issuers.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.